Advertisement

Advertisement

ALLO Stock Latest News

Allogene Therapeutics files $500M mixed securities shelf

The FlyAllogene Therapeutics files $500M mixed securities shelf

Allogene Therapeutics reports Q2 EPS (13c), consensus (15c)

PremiumThe Fly

Allogene Therapeutics reports Q2 EPS (13c), consensus (15c)

5d ago

Tyler Van Buren Reiterates Buy on Allogene, Citing Strong ALPHA3 Trial Momentum and De-Risking Efficacy/Safety Data for Off-the-Shelf CAR-T Cema-cel

PremiumRatings

Tyler Van Buren Reiterates Buy on Allogene, Citing Strong ALPHA3 Trial Momentum and De-Risking Efficacy/Safety Data for Off-the-Shelf CAR-T Cema-cel

9d ago

Allogene Therapeutics (ALLO) Q2 Earnings Cheat Sheet

PremiumPre-Earnings

Allogene Therapeutics (ALLO) Q2 Earnings Cheat Sheet

12d ago

Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel

PremiumThe Fly

Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel

24d ago

Allogene publishes Phase 1 data in Journal of Clinical Oncology

PremiumThe FlyAllogene publishes Phase 1 data in Journal of Clinical Oncology

1M ago

Citizens biotech analyst holds an analyst/industry conference call

The Fly

Citizens biotech analyst holds an analyst/industry conference call

2M ago

Citizens biotech analysts hold an analyst/industry conference call

The Fly

Citizens biotech analysts hold an analyst/industry conference call

2M ago

Allogene Launches ATM Offering to Bolster Capital Flexibility

PremiumCompany Announcements

Allogene Launches ATM Offering to Bolster Capital Flexibility

2M ago

Allogene Therapeutics Names Zachary Roberts as New CEO

PremiumCompany Announcements

Allogene Therapeutics Names Zachary Roberts as New CEO

3M ago

Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO

PremiumThe Fly

Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO

3M ago

Allogene Earnings Call Highlights Early CAR-T Momentum

PremiumCompany Announcements

Allogene Earnings Call Highlights Early CAR-T Momentum

3M ago

Allogene Therapeutics Balances Bold Data With Rising Spend

PremiumCompany AnnouncementsAllogene Therapeutics Balances Bold Data With Rising Spend

3M ago

Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors

Company Announcements

Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors

3M ago

Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)

The Fly

Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)

3M ago

Allogene Highlights ALPHA3 Data and Extended Cash Runway

PremiumCompany Announcements

Allogene Highlights ALPHA3 Data and Extended Cash Runway

3M ago

Allogene Therapeutics increases 2026 operating cash expense guidance

PremiumThe Fly

Allogene Therapeutics increases 2026 operating cash expense guidance

3M ago

Allogene Therapeutics options imply 10.6% move in share price post-earnings

PremiumThe Fly

Allogene Therapeutics options imply 10.6% move in share price post-earnings

3M ago

ALLO Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

ALLO Upcoming Earnings Report: What to Expect?

3M ago

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

PremiumThe FlyAllogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

4M ago

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

The Fly

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

4M ago

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

The Fly

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >